CN102205046A - Medicament for reducing blood fat - Google Patents
Medicament for reducing blood fat Download PDFInfo
- Publication number
- CN102205046A CN102205046A CN 201110120120 CN201110120120A CN102205046A CN 102205046 A CN102205046 A CN 102205046A CN 201110120120 CN201110120120 CN 201110120120 CN 201110120120 A CN201110120120 A CN 201110120120A CN 102205046 A CN102205046 A CN 102205046A
- Authority
- CN
- China
- Prior art keywords
- parts
- medicament
- blood fat
- rhizoma
- grams
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 25
- 210000004369 blood Anatomy 0.000 title claims abstract description 14
- 239000008280 blood Substances 0.000 title claims abstract description 14
- 241001164374 Calyx Species 0.000 claims abstract description 7
- 241000005787 Cistanche Species 0.000 claims abstract description 7
- 229940079593 drug Drugs 0.000 claims description 6
- 210000000582 semen Anatomy 0.000 claims description 6
- 239000009636 Huang Qi Substances 0.000 claims description 4
- 244000064622 Physalis edulis Species 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 3
- 241001106044 Physalis Species 0.000 claims description 2
- 241000545442 Radix Species 0.000 claims description 2
- 239000007919 dispersible tablet Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- -1 instant Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 8
- 230000008901 benefit Effects 0.000 abstract description 2
- 241000049624 Alisma plantago-aquatica subsp. orientale Species 0.000 abstract 1
- 241001061264 Astragalus Species 0.000 abstract 1
- 241000212322 Levisticum officinale Species 0.000 abstract 1
- 241000830535 Ligustrum lucidum Species 0.000 abstract 1
- 240000002948 Ophiopogon intermedius Species 0.000 abstract 1
- 241001465382 Physalis alkekengi Species 0.000 abstract 1
- 244000088415 Raphanus sativus Species 0.000 abstract 1
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 abstract 1
- 244000153955 Reynoutria sachalinensis Species 0.000 abstract 1
- 235000003202 Reynoutria sachalinensis Nutrition 0.000 abstract 1
- 235000006533 astragalus Nutrition 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- 241000411851 herbal medicine Species 0.000 abstract 1
- 239000001645 levisticum officinale Substances 0.000 abstract 1
- 210000004233 talus Anatomy 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 6
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 5
- 208000032928 Dyslipidaemia Diseases 0.000 description 4
- 208000017170 Lipid metabolism disease Diseases 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Abstract
The invention relates to a medicament for reducing blood fat, which is prepared from the following Chinese herbal medicines in part by weight: 10 to 20 parts of oriental waterplantain rhizome, 20 to 30 parts of lantern plant calyx, 10 to 30 parts of astragalus, 20 to 50 parts of radish seed, 5 to 15 parts of Szechuan lovage rhizome, 5 to 15 parts of desertliving cistanche, 5 to 10 parts of dwarf lilyturf tuber, 10 to 20 parts of glossy privet fruit and 10 to 20 parts of giant knotweed rhizome. Due to the adoption of natural medicaments, the medicament for reducing the blood fat has the advantages of quick response, good curative effect and no toxic or side effect.
Description
Technical field
The present invention relates to field of medicaments, specifically, relate to a kind of medicament of blood fat reducing.
Background technology
Hyperlipemia mainly be meant serum total cholesterol (TC) or triglyceride (TG) level too high and (or) serum high-density LP-cholesterol (HDL-C) level is low excessively.Hyperlipemia is person in middle and old age's commonly encountered diseases and a frequently-occurring disease, and along with the raising of people's living standard and the change of living habit, this sick sickness rate obviously increases, and the age of morbidity also shifts to an earlier date to some extent.The caused atherosclerosis of hyperlipemia is to cause the main cause of coronary heart disease, hypertension and cerebrovascular disease, and the whole world has 1,200 ten thousand people to die from cardiovascular diseases and apoplexy every year approximately.So the treatment of hyperlipemia is extremely important, this has caused showing great attention to of the whole mankind.The final purpose of treatment hyperlipemia is to suppress arteriosclerotic further developing, thereby prevents the death that caused by cardio-cerebrovascular diseases.
Summary of the invention
The medicament that the purpose of this invention is to provide a kind of blood fat reducing.
In order to realize purpose of the present invention, the invention provides a kind of medicament of blood fat reducing, it is to be made by weight by following bulk drugs: Rhizoma Alismatis 10-20 part, Calyx seu Fructus physalis 20-30 part, Radix Astragali 10-30 part, Semen Raphani 20-50 part, Rhizoma Chuanxiong 5-15 part, Herba Cistanches 5-15 part, Radix Ophiopogonis 5-10 part, Fructus Ligustri Lucidi 10-20 part and Rhizoma Polygoni Cuspidati 10-20 part.
Preferably, it is to be made by weight by following bulk drugs: 15 parts of 15 parts of Rhizoma Alismatis, 25 parts of Calyx seu Fructus physaliss, 20 parts of the Radixs Astragali, 30 parts of Semen Raphanis, 10 parts of Rhizoma Chuanxiongs, 10 parts of Herba Cistanches, 8 parts of Radix Ophiopogonis, 15 parts of Fructus Ligustri Lucidi and Rhizoma Polygoni Cuspidati.
Preferably, described medicament is tablet, dispersible tablet, instant, powder or granule.
The present invention also provides a kind of medicaments preparation method of blood fat reducing, this method comprises: get Rhizoma Alismatis 150 gram, Calyx seu Fructus physalis 250 grams, the Radix Astragali 200 grams, Semen Raphani 300 grams, Rhizoma Chuanxiong 100 grams, Herba Cistanches 100 grams, Radix Ophiopogonis 80 gram, Fructus Ligustri Lucidi 150 grams and Rhizoma Polygoni Cuspidati 150 grams, pulverize, cross 100 mesh sieves, add sucrose 300 grams then, mixing is packed in 100 bags promptly.
Use natural drug in the medicament of blood fat reducing of the present invention, so its advantage that has instant effect, good effect, has no side effect.
The specific embodiment
Below the invention will be further described for the description by the specific embodiment, but this is not to be limitation of the present invention, those skilled in the art are according to basic thought of the present invention, can make various modifications or improvement, but only otherwise break away from basic thought of the present invention, all within the scope of the present invention.
The preparation of embodiment 1 powder of the present invention
Get Rhizoma Alismatis 150 gram, Calyx seu Fructus physalis 250 grams, the Radix Astragali 200 grams, Semen Raphani 300 grams, Rhizoma Chuanxiong 100 grams, Herba Cistanches 100 grams, Radix Ophiopogonis 80 gram, Fructus Ligustri Lucidi 150 grams and Rhizoma Polygoni Cuspidati 150 grams, pulverize, cross 100 mesh sieves, add sucrose 300 grams then, mixing is packed in 100 bags promptly.
Experimental example
This group of clinical data case 50 examples, all meet hyperlipemia diagnostic criteria (the dyslipidemia diagnostic criteria that " Chinese cardiovascular magazine " editorial board dyslipidemia Preventing Countermeasures special topic group is formulated) [Chinese cardiovascular diseases's magazine editorial board. dyslipidemia Preventing Countermeasures special topic group. dyslipidemia control suggestion [J]. Chinese cardiovascular diseases's magazine, 1997,25 (3): 169.], wherein male 25 examples, women 25 examples; 35～71 years old age, average 52 years old.
Use the medicine that makes among the embodiment 1 to treat, wherein one day 2 times, each one bag, treating March is a course of treatment.
Reference " new Chinese medicine clinical research guideline " (the Zheng Xiao cornel. new Chinese medicine clinical research guideline (trying) [S]. Beijing. Chinese Medicine science and technology publishing house, 2002:85～89.) the formulation criterion of therapeutical effect.Respectively before and after the treatment all on an empty stomach behind the 12h in the venous blood samples in early morning, measure every indexs such as TC, TG, LDL-C, HDL-C, conscience, renal function and blood, urine, stool routine.Produce effects: lipids detection reaches following each person: TC and descends 〉=20%, and TG descends 〉=40%.HDL-C rising 〉=0.26mmol/L, TC-LDL-C/HDL-C 〉=20%.Effectively: lipids detection reach following each person: TC descend 〉=10% but＜20%, TG descend 〉=20% but＜40%.HDL-C rising 〉=0.104mmol/L but＜0.26mmol/L, TC-LDL-C/HDL-C 〉=10% but＜20%.Invalid: lipids detection does not reach above standard person.
Through the observation of a course of treatment is arranged, finding has 45 patient treatment effect produce effects, and 5 patient treatment effects are effective, and the total effective rate rate is 100%, and does not observe tangible untoward reaction during whole treatment.
After treating a course of treatment, all the patient is followed up a case by regular visits to weekly, continue half a year, find the sign of recurrence.
Claims (3)
1. the medicament of a blood fat reducing, it is characterized in that it is to be made by weight by following bulk drugs: Rhizoma Alismatis 10-20 part, Calyx seu Fructus physalis 20-30 part, Radix Astragali 10-30 part, Semen Raphani 20-50 part, Rhizoma Chuanxiong 5-15 part, Herba Cistanches 5-15 part, Radix Ophiopogonis 5-10 part, Fructus Ligustri Lucidi 10-20 part and Rhizoma Polygoni Cuspidati 10-20 part.
2. the medicament of blood fat reducing according to claim 1, it is characterized in that it is to be made by weight by following bulk drugs: 15 parts of 15 parts of Rhizoma Alismatis, 25 parts of Calyx seu Fructus physaliss, 20 parts of the Radixs Astragali, 30 parts of Semen Raphanis, 10 parts of Rhizoma Chuanxiongs, 10 parts of Herba Cistanches, 8 parts of Radix Ophiopogonis, 15 parts of Fructus Ligustri Lucidi and Rhizoma Polygoni Cuspidati.
3. the medicament of blood fat reducing according to claim 1 and 2 is characterized in that, described medicament is tablet, dispersible tablet, instant, powder or granule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011101201201A CN102205046B (en) | 2011-05-11 | 2011-05-11 | Medicament for reducing blood fat |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011101201201A CN102205046B (en) | 2011-05-11 | 2011-05-11 | Medicament for reducing blood fat |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102205046A true CN102205046A (en) | 2011-10-05 |
| CN102205046B CN102205046B (en) | 2012-07-04 |
Family
ID=44694289
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011101201201A Expired - Fee Related CN102205046B (en) | 2011-05-11 | 2011-05-11 | Medicament for reducing blood fat |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102205046B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104174004A (en) * | 2014-09-11 | 2014-12-03 | 彭海明 | Medicament for lowering blood fat |
| CN104367788A (en) * | 2014-10-31 | 2015-02-25 | 海南金海岸生物技术研究所 | Pharmaceutical composition compounded with marine organism polysaccharide as well as preparation method and application of pharmaceutical composition |
| CN105816624A (en) * | 2016-04-13 | 2016-08-03 | 林南平 | Medicine for treating hyperlipidaemia |
| CN107714823A (en) * | 2017-11-07 | 2018-02-23 | 黄建文 | A kind of pharmaceutical composition of reducing blood lipid |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101874862A (en) * | 2009-04-30 | 2010-11-03 | 滕淑香 | Traditional Chinese medicine for treating hyperlipidemia |
-
2011
- 2011-05-11 CN CN2011101201201A patent/CN102205046B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101874862A (en) * | 2009-04-30 | 2010-11-03 | 滕淑香 | Traditional Chinese medicine for treating hyperlipidemia |
Non-Patent Citations (1)
| Title |
|---|
| 《天津中医》 20000612 于慧雯 高脂血症中医药治疗进展 51-53 1-3 第17卷, 第03期 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104174004A (en) * | 2014-09-11 | 2014-12-03 | 彭海明 | Medicament for lowering blood fat |
| CN104367788A (en) * | 2014-10-31 | 2015-02-25 | 海南金海岸生物技术研究所 | Pharmaceutical composition compounded with marine organism polysaccharide as well as preparation method and application of pharmaceutical composition |
| CN105816624A (en) * | 2016-04-13 | 2016-08-03 | 林南平 | Medicine for treating hyperlipidaemia |
| CN107714823A (en) * | 2017-11-07 | 2018-02-23 | 黄建文 | A kind of pharmaceutical composition of reducing blood lipid |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102205046B (en) | 2012-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100475232C (en) | Oral medicine for treating diabetes and use thereof | |
| CN102205046B (en) | Medicament for reducing blood fat | |
| CN102727706A (en) | Composition for preventing and treating diabetes | |
| CN101947300B (en) | Traditional Chinese medicinal composition for treating liver diseases, preparation method thereof and use thereof | |
| CN1985922A (en) | Medicine composition for treating common cold and its preparing method | |
| CN102102079A (en) | Blood pressure-reducing table vinegar and preparation method thereof | |
| CN102631647A (en) | Chinese patent medicine mixture for treating acute urticaria | |
| CN103463464B (en) | A kind of to the medicative healthy medicated wine of diabetes tool | |
| CN102293936A (en) | Medicinal composition or health food composition for protecting gastric mucosa, and preparation method thereof | |
| CN102726708A (en) | Health-care food for lowering blood pressure | |
| CN103977390B (en) | A kind of preparation method and its usage of ginger onion medicated wine composition | |
| CN108379461B (en) | Graphene blood pressure lowering patch and preparation method thereof | |
| CN103083429B (en) | Blood fat-reducing traditional Chinese medicine formula | |
| CN101904935A (en) | Chinese medicinal composition for improving immunity of organisms, tonifying middle-jiao and qi and treating canine distemper | |
| CN102764294A (en) | Cough relieving and sputum eliminating combination and preparation method thereof | |
| CN100548363C (en) | Medicine of treatment benign prostate hyperplasia and preparation method thereof | |
| CN102119776A (en) | Dried orange peel extract and preparation method and use thereof | |
| CN102008705B (en) | Medicinal and edible dual-purpose ginger-date ying-wei particle used for cold at early stage | |
| CN102068520B (en) | Chinese medicinal composition for treating cardiovascular and cerebrovascular diseases and preparation method thereof | |
| CN104174004A (en) | Medicament for lowering blood fat | |
| CN104491418B (en) | A kind of Chinese medicine preparation for treating ulcerative colitis | |
| CN101028311B (en) | Use of selaginella tamariscina | |
| CN103142975B (en) | Medicament for reducing blood fat | |
| CN104367788A (en) | Pharmaceutical composition compounded with marine organism polysaccharide as well as preparation method and application of pharmaceutical composition | |
| CN101147785A (en) | Medicinal preparation for preventing tumor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: TIANJIANG PHARMACEUTICAL INDUSTRY CO., LTD., JIANG Free format text: FORMER OWNER: LI JIE Effective date: 20130726 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 272111 JINING, SHANDONG PROVINCE TO: 214400 WUXI, JIANGSU PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20130726 Address after: 214400 Jiangyin Economic Development Zone, Jiangsu, Qin Shan Road, No. 8 Patentee after: Tianjiang Pharmaceutical Industry Co., Ltd., Jiangyin Address before: 272111 Pharmacy Department of first people's Hospital of Shandong, Jining Province Patentee before: Li Jie |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20160617 Address after: 200331 2948, room 105, 2891 lane, South Qilian Mountains Road, Shanghai, Putuo District Patentee after: Shanghai rich medical technology Co., Ltd. Address before: 214400 Jiangyin Economic Development Zone, Jiangsu, Qin Shan Road, No. 8 Patentee before: Tianjiang Pharmaceutical Industry Co., Ltd., Jiangyin |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20160818 Address after: 201209 Shanghai city Pudong New Area Sichuan Road No. 6251 building 11 Room 309 Patentee after: Shanghai Jingyuan Investment Co., Ltd. Address before: 200331 2948, room 105, 2891 lane, South Qilian Mountains Road, Shanghai, Putuo District Patentee before: Shanghai rich medical technology Co., Ltd. |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120704 Termination date: 20180511 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |